Results 201 to 210 of about 3,844,628 (256)
This study investigates intracellular (IC) exposure of tenofovir alafenamide (TAF) and its clinical determinants in experienced people living with HIV. We conducted a monocentric retrospective analysis of 86 adults treated with either bictegravir (BIC)‐ or dolutegravir (DTG)‐containing regimen. Plasma and IC trough concentrations (Ctrough) of tenofovir
Micol Ferrara +10 more
wiley +1 more source
What Makes an “Ideal” Cell Line for Recombinant Adeno‐Associated Virus Production?
Several host cell types have been used to produce rAAVs to date. Cell line‐specific traits that are beneficial in the context of rAAV manufacturing are reviewed here, with the goal of developing a consensus on the ‘ideal’ characteristics that an rAAV production host should possess (created with Biorender.com).
James Conheady +6 more
wiley +1 more source
ABSTRACT Single‐stranded DNA (ssDNA) solutions are promising innovations shaping the future of genetic research and medical therapies. In principle, biotechnological mass production of ssDNA can be achieved using Escherichia coli in a high‐cell density fed‐batch process by secreting phagemid particles derived from the filamentous M13 bacteriophages ...
Nathalie Hafner +4 more
wiley +1 more source
Induction and Enhancement of Bacteriocin Production (Review)
ABSTRACT Conventionally, bacteriocins are produced by microorganisms on complex substrates, released as semi‐purified preparations or crude fermentates. These bacteriocin‐containing products often exhibit unsatisfactory purity, low active‐substance content, and high production costs, limiting their commercialization and use. This review aims to analyze
Oksana Knysh, Artur Martynov
wiley +1 more source
Accelerating green heterocyclic synthesis: Convergence of AI, automation, and sustainable chemistry
Green heterocyclic synthesis and data‐driven tools such as AI, high‐throughput experimentation, continuous flow, and self‐driving laboratories have developed largely in parallel. This review connects them and asks how green metrics such as E‐factor and PMI might serve as explicit optimization targets rather than post‐hoc measures, toward sustainable ...
Noor Aisyah Ahmad Shah +8 more
wiley +1 more source
Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim +9 more
wiley +1 more source
A probiotic spore‐based drug delivery system (BCS‐Que@ApNPs) provides excellent targeted delivery, bioresponsive drug release, and long‐term retention (over 48 h), making it suitable for oral treatment of inflammatory bowel disease and its associated anxiety and depression.
Qingling Song +9 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Direct-acting antiviral retreatment patterns for hepatitis C
Journal of Managed Care & Specialty Pharmacy, 2022BACKGROUND: Despite the strong efficacy of direct-acting antivirals (DAAs) against the hepatitis C virus, many patients require a second regimen of DAA treatment. However, limited research exists to characterize rates of retreatment across different DAA agents or potential factors that may increase retreatment risk.
Shaquib Al, Hasan +3 more
openaire +2 more sources
Benefits of Direct-Acting Antivirals for Hepatitis C
Annals of Internal Medicine, 2017Emerging data show that direct-acting antivirals (DAAs) improve clinical outcomes in hepatitis C virus (HCV).
Anna S, Lok +5 more
openaire +2 more sources
Management of direct-acting antiviral agent failures
Journal of Hepatology, 2015Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment registration studies, with rates of 1% to 7%, depending on the patients' baseline characteristics. In real life, failure is slightly higher, likely because of lower compliance.
Maria, Buti +2 more
openaire +2 more sources

